Urban adolescents with asthma often have inadequate preventive care. We tested the effectiveness of the school-based asthma care for teens (SB-ACT) program on asthma morbidity and preventive medication adherence. METHODS: SUBJECTS/SETTING: 12 to 16yr olds with persistent asthma in Rochester, NY schools. DESIGN: 3-group randomized trial (2014 to 2019). SB-ACT intervention -- two core components: (1) directly observed therapy (DOT) of preventive asthma medications, provided in school for at least 6 to 8 weeks for the teen to learn proper technique and experience the benefits of daily preventive therapy; (2) 4 to 6 weeks later, 3 sessions of motivational interviewing (MI) to discuss potential benefits from DOT and enhance motivation to take medication independently. We included 2 comparison groups: (1) DOT-only for 6 to 8 wks, and (2) asthma education (AE) attention control. Masked follow-up assessments were conducted at 3, 5, and 7 mos. OUTCOMES: Mean number of symptom-free days (SFDs)/2 weeks and medication adherence. ANALYSES: Modified intention-to-treat repeated measures analysis. RESULTS: We enrolled 430 teens (56% Black, 32% Hispanic, 85% Medicaid). There were no group differences at baseline. We found no difference in SFDs at any follow-up timepoint. More teens in the SB-ACT and DOT-only groups reported having a preventive asthma medication at each follow-up (p < 0.001), and almost daily adherence at 3 and 5-months (p < 0.001, p = 0.003) compared to AE. By 7 months there were no significant differences between groups in adherence (p = 0.49). CONCLUSION: SB-ACT improved preventive medication availability and short-term adherence but did not impact asthma symptoms. Further work is needed to create developmentally appropriate and effective interventions for this group.

Full text (sometimes free) may be available at these link(s):      help

• DOI
• PubMed
• PDF locator
• publisher